GLP-1 Medications Explained: Benefits, Side Effects, and What to Expect
GLP-1 medications can support blood-sugar management and long-term weight reduction for eligible people, but the products are not interchangeable and each has its own approved uses, benefits, side effects, and warnings.
Key takeaways
- GLP-1 is a naturally occurring hormone involved in blood-sugar regulation, appetite, and digestion.
- Some GLP-1 medicines are approved for type 2 diabetes; others are approved for chronic weight management or additional product-specific uses.
- Tirzepatide activates both GIP and GLP-1 receptors, so it is a dual GIP/GLP-1 receptor agonist.
- Nausea, diarrhea, vomiting, constipation, and abdominal discomfort are among the most common side effects.
- Nutrition, hydration, resistance exercise, and long-term planning still matter during treatment.
GLP-1 medications have changed how clinicians approach type 2 diabetes and chronic weight management. They can improve blood-sugar control, reduce appetite, and help eligible patients lose weight. But “GLP-1” is a broad label: different products have different active ingredients, approved uses, dosing schedules, warnings, and evidence.
This guide explains the category in plain language, including how the medications work, what benefits are realistic, which side effects are common, and why nutrition and strength training remain important.
What is GLP-1?
GLP-1 stands for glucagon-like peptide-1. The body releases this hormone after food is consumed. Among its functions, GLP-1 helps stimulate insulin release when blood sugar is elevated, reduce glucagon secretion, slow movement of food through the stomach, and influence appetite and fullness.
GLP-1 receptor agonists imitate some of these effects by binding to and activating the GLP-1 receptor. Tirzepatide works differently: it activates both the GIP and GLP-1 receptors.
What are GLP-1 medications used for?
The approved use depends on the exact product—not only the active ingredient. Some products are approved to improve blood-sugar control in people with type 2 diabetes. Others are approved for chronic weight management in eligible adults and, for some products, adolescents. Certain products also have additional cardiovascular or other indications listed in their current FDA labeling.
| Active ingredient | Drug type | Examples of approved uses |
|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Type 2 diabetes or chronic weight management, depending on the product |
| Liraglutide | GLP-1 receptor agonist | Type 2 diabetes or chronic weight management, depending on the product |
| Dulaglutide | GLP-1 receptor agonist | Type 2 diabetes |
| Tirzepatide | Dual GIP/GLP-1 receptor agonist | Type 2 diabetes or chronic weight management, depending on the product |
The National Institute of Diabetes and Digestive and Kidney Diseases lists liraglutide, semaglutide, and tirzepatide among the FDA-approved medications used for long-term weight management in qualifying patients.
How do they support blood-sugar management?
GLP-1 receptor agonists can increase insulin release when blood glucose is elevated and reduce glucagon activity. These effects can help lower blood sugar in people with type 2 diabetes. Because the insulin response is glucose-dependent, the effect is linked to glucose levels. However, the risk of hypoglycemia can increase when a GLP-1 medicine is combined with insulin or medicines that stimulate insulin release.
The American Diabetes Association’s 2026 Standards of Care recommend considering GLP-1 receptor agonist or dual GIP/GLP-1 therapy with greater weight-loss efficacy for many adults who have both type 2 diabetes and overweight or obesity. Selection still needs to be individualized.
How do they support weight management?
These medicines can reduce appetite, increase fullness, and make smaller portions more manageable. Their effects on digestion and appetite-regulating pathways can help some people sustain a reduced-calorie eating pattern.
A 2025 systematic review and meta-analysis of 47 randomized controlled trials found that GLP-1 receptor agonists reduced body weight, body mass index, and waist circumference in people with overweight or obesity. Results varied by medication, dose, treatment duration, and study population.
Medication is generally one part of a larger plan. FDA-approved weight-management products are used alongside nutrition and physical-activity measures, not as replacements for them.
Potential benefits
Depending on the medication, approved indication, and patient population, potential benefits may include:
- Improved blood-sugar control
- Reduced appetite
- Clinically meaningful weight reduction
- Improvement in certain obesity-related conditions
- Cardiovascular or other benefits in specific groups and with specific products
- Maintenance of weight reduction during continued treatment
A benefit demonstrated for one medicine or one population should not automatically be applied to every product in the category.
Common side effects
Gastrointestinal side effects are common, especially when treatment begins or the dose is increased. Depending on the product, these may include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain or discomfort
- Indigestion
- Reduced appetite
Product labels use gradual dose-escalation schedules to improve tolerability. A prescribed dose should not be increased, decreased, or otherwise changed outside the product instructions and the prescribing plan.
Important risks and safety considerations
Warnings differ by drug and product. Current FDA prescribing information for GLP-1 and dual GIP/GLP-1 medicines may include warnings involving:
- Acute pancreatitis
- Gallbladder disease
- Severe gastrointestinal reactions
- Kidney injury associated with volume depletion
- Hypoglycemia when combined with certain diabetes treatments
- Serious allergic reactions
- Delayed stomach emptying and considerations around anesthesia or deep sedation
Some products carry a boxed warning about thyroid C-cell tumors observed in rodents. It is unknown whether the same risk applies to humans. These products are generally contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Check the current label for the exact product.
Know the urgent warning signs
Prompt medical attention is important for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, fainting, confusion, signs of a serious allergic reaction, or other rapidly worsening symptoms.
Why nutrition still matters
A large reduction in appetite can make it harder to consume enough protein, fiber, fluids, vitamins, and minerals. Eating as little as possible is not the goal. A sustainable plan emphasizes nutrient-dense foods in portions that are tolerated.
Useful priorities often include a protein source at meals, produce or another tolerated fiber source, steady fluid intake, and meal sizes that do not worsen nausea or uncomfortable fullness.
Muscle preservation during weight loss
Weight loss can include reductions in both fat mass and lean mass. Recent systematic reviews show that body-composition changes vary across studies, medications, and populations. Resistance training appears especially valuable when the goal is to protect function and lean tissue during weight loss.
- Eat an appropriate amount of protein across the day.
- Perform resistance exercise consistently.
- Avoid unnecessarily extreme calorie restriction.
- Monitor strength and physical function—not only scale weight.
Protein needs are not one-size-fits-all. Kidney disease, pregnancy, age, activity level, and other factors can materially change an appropriate target.
Hydration and digestive symptoms
Vomiting, diarrhea, reduced food intake, and constipation can all affect hydration. Drinking manageable amounts at predictable points across the day is often easier than trying to catch up all at once.
Very limited urination, faintness, confusion, or inability to keep fluids down are not routine inconveniences and need prompt attention.
What happens after stopping treatment?
Weight regain can occur after GLP-1 treatment is discontinued. A 2025 systematic review and meta-analysis found measurable weight and metabolic rebound after discontinuation, although the amount varied by medication, population, and follow-up period. The ADA’s 2026 guidance similarly notes that stopping chronic obesity pharmacotherapy often leads to recurrence of weight gain.
Before starting, it is useful to understand the long-term plan: how progress will be monitored, whether ongoing treatment may be appropriate, what lifestyle support will continue, and what options exist if cost, side effects, pregnancy planning, or another issue requires a change.
Compounded, counterfeit, and unapproved GLP-1 products
Compounded medicines are not FDA-approved and do not undergo the same premarket review for safety, effectiveness, and quality. In 2026, the FDA continued to warn about fraudulent compounded products, dosing errors, products sold illegally online, and substances marketed directly to consumers as “research use only.”
The FDA advises using a state-licensed pharmacy and notes that a compounded drug may be appropriate when a patient’s medical need cannot be met by an FDA-approved product. Products of unknown origin, counterfeit products, and materials labeled only for research use should not be treated as equivalent to an FDA-approved prescription medicine.
Questions to ask before starting
- What condition is this exact product approved to treat?
- What benefits are realistic for me?
- What side effects are most likely, and which ones are urgent?
- Could it interact with my current medications?
- How will dose escalation and side effects be monitored?
- How should nutrition, hydration, and activity be adjusted?
- What is the long-term plan if the medication works?
Frequently asked questions
Are all GLP-1 medications the same?
No. They differ in active ingredient, receptor activity, formulation, approved use, dose, schedule, effectiveness, warnings, and side effects.
Is tirzepatide technically a GLP-1 medication?
It is often included in GLP-1 discussions, but it is technically a dual GIP/GLP-1 receptor agonist.
Can someone combine two GLP-1 medications?
Product labeling can specifically advise against combining a medicine with another product containing the same active ingredient or another GLP-1 receptor agonist. These medicines should not be combined unless the applicable prescribing information and prescriber support that plan.
Do these medications eliminate the need for nutrition and exercise?
No. FDA-approved weight-management products are intended to be used alongside nutrition and physical-activity measures.
Does everyone experience nausea?
No. Tolerability differs. Some people report minimal symptoms, while others have difficulty continuing treatment.
Can these medications be used during pregnancy?
Weight-loss medication is generally not used during pregnancy. Product-specific labeling should be checked for pregnancy, breastfeeding, and how long a medicine should be stopped before a planned pregnancy.
The bottom line
GLP-1 receptor agonists and dual GIP/GLP-1 medicines can be valuable tools for appropriate patients. The strongest plan pairs product-specific medical care with adequate nutrition, physical activity, resistance exercise, hydration, and realistic long-term expectations.
References
- U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. Revised 2026.
- U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. 2025.
- National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight & Obesity.
- American Diabetes Association Professional Practice Committee. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S166–S182.
- Wong HJ, et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight. Diabetes Care. 2025;48(2):292–300.
- Karakasis P, et al. Effect of GLP-1 receptor agonists and co-agonists on body composition. Metabolism. 2025;156113.
- Tzang CC, et al. Metabolic rebound after GLP-1 receptor agonist discontinuation. EClinicalMedicine. 2025;90:103680.
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Updated 2026.
Last reviewed: July 29, 2026
Medical disclaimer: This article is provided for general educational purposes only. It is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease. Medication decisions should be made with a qualified healthcare professional who understands your medical history and the current prescribing information for the exact product.